Regeneron shares slump on worries about Praluent limits; Teva switches M&A law firms on Mylan conflict;

@FiercePharma: GSK, Sanofi hauled up by India's competition watchdog on vaccine tenders. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for Pfizer at its Agila plants in India. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Does brand + generic really add up? Sandoz, Actavis execs count the ways. Article | Follow @CarlyHFierce

> Regeneron ($REGN) shares slumped Wednesday on an FDA panel meeting's vote to approve its anti-cholesterol drug Praluent, developed with Sanofi ($SNY), on worries that the agency will restrict its target population. Report

> Teva Pharmaceutical Industries ($TEVA) switched law firms in its bid to buy fellow generics maker Mylan ($MYL), after a U.S. court recommended against Kirkland & Ellis because it had a pre-existing relationship with Mylan. Report

> One dose of GlaxoSmithKline's ($GSK) human papillomavirus vaccine Cervarix, rather than the currently recommended two, could be enough to prevent the majority of cervical cancers, scientists said. Report

> The National Institute for Health and Care Excellence (NICE) turned down Celgene's ($CELG) Otezla as a treatment for chronic plaque psoriasis on cost-effectiveness grounds. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: HeartWare tells patients how to safely use its blood pump in attempt to overcome slew of recent recalls. Article | Follow @FierceMedDev

@VarunSaxena2: India's Cipla gets first FDA approval of oral pellet to treat HIV/AIDS in infants. FierceDrugDelivery article | Follow @VarunSaxena2

> Biotronik's vascular stent determined effective in challenging cases of peripheral artery disease. Story

> KKR-backed Panasonic Healthcare to buy Bayer diabetes device biz for almost $1.2B. Article

Biotech News

@FierceBiotech: ICYMI: Sanofi and Regeneron's would-be blockbuster clears FDA hurdle, but questions remain. Article | Follow @FierceBiotech

@JohnCFierce: Melinta grabs $67M in pursuit of a big PhIII antibiotics finish, NDA. News | Follow @JohnCFierce

@DamianFierce: This seems to be driving the PCSK9 panelists insane. Item | Follow @DamianFierce

> AstraZeneca R&D chief Briggs Morrison makes an unexpected exit. News

> Merck aces Phase III with knockoffs of Enbrel and Remicade. Article

> SEC: Insider traders lined their pockets on AstraZeneca's $1.3B Ardea deal. Report

Pharma Marketing News

> Merck KGaA's amped-up consumer pitch delivers much-needed sales hike. Story

> Pharma needs some 'marriage counseling' for patient relationships: report. More

> Merck's best hep C strategy is niche marketing, game theory expert figures. Story

> Want new patient relationships? Digital-savvy KOLs could be your intro. Article

> Why sue, FDA asks Amarin: You can spread the word on Vascepa already. Item

Biotech Research News

> CRISPR-Cas9 furor highlights explosive growth of gene editing in China. Report

> Do U.S. biomedical researchers really waste about $28B a year? Story

> Enzyme in mice linked to obesity, diabetes. Item

> NYU study: Blocking receptor protein CXCR4 'decimated' leukemia cells. More

> ALS researchers at Gladstone, Michigan shed new light on a key drug target. Article

Diagnostics News

> Study identifies 16 new genetic variants of Bloom syndrome. News

> U.K. researchers say earlier diagnoses of bladder cancer needed, especially among women. Report

> Health Diagnostic Laboratory rails against physician kickback claims. Story

> Roche receives FDA clearance for test to diagnose herpes using its cobas system. Article

> Exact Sciences joins forces with MD Anderson for lung cancer Dx development. More

And Finally... An Indian woman with drug-resistant tuberculosis who flew in to Chicago in April is now being treated for the disease at the National Institutes of Health in Bethesda, MD. Report